antipsychotic

Pharma

BMS touts commercial execution, reckons with clinical setbacks

Four failed phase 3 trials of BMS' growth products "collectively have relatively limited impact on the long-term growth of the company," the CEO said.

Angus Liu Jul 31, 2025 11:10am

BMS' schizophrenia drug stumbles in blow to blockbuster plan

Apr 23, 2025 10:35am

Close-up of a hand next to a Lyndra capsule and the star shape it opens into in the stomach

Gilead-backed Lyndra lays off staff as it nears pivotal data

Sep 15, 2023 3:33pm

FDA advisers back Rexulti new use in nearly unanimous vote

Apr 14, 2023 9:24pm

Sanofi offloads rights to prolonged-release antipsychotic drug

Apr 26, 2022 10:18am

Intra-Cellular's Caplyta gains label expansion with bipolar nod

Dec 20, 2021 4:45pm